Chimerix

Emergent BioSolutions

Pharma

Emergent finalizes deal for Chimerix's smallpox drug Tembexa

Emergent BioSolutions completed its acquisition of oral antiviral Tembexa from Chimerix, giving the U.S. another potential treatment for monkeypox.

Kevin Dunleavy Sep 27, 2022 9:15am

HHS

HHS earmarks $680M for smallpox drug, an Emergent buyout target

Aug 29, 2022 11:50am

Smallpox stock image

Emergent adds another arrow to its medical ountermeasures quiver

May 16, 2022 2:29pm

FDA

FDA approves Chimerix's oral suspension smallpox antiviral

Jun 8, 2021 7:30am